{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T07:09:38Z","timestamp":1774681778608,"version":"3.50.1"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology - Research and Practice"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.prp.2022.153897","type":"journal-article","created":{"date-parts":[[2022,4,13]],"date-time":"2022-04-13T01:53:29Z","timestamp":1649814809000},"page":"153897","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Distinct expression signatures of miR-130a, miR-301a, miR-454 in formalin fixed paraffin embedded tissue samples of prostate cancer patients"],"prefix":"10.1016","volume":"234","author":[{"given":"Esra","family":"Bozgeyik","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Onur","family":"Ceylan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.prp.2022.153897_bib1","doi-asserted-by":"crossref","first-page":"5531","DOI":"10.1007\/s11033-021-06568-7","article-title":"Identification of miRNA signatures and their therapeutic potentials in prostate cancer","volume":"48","author":"Karadag","year":"2021","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.prp.2022.153897_bib2","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA: a Cancer J. Clin."},{"key":"10.1016\/j.prp.2022.153897_bib3","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1016\/S0140-6736(14)60525-0","article-title":"Screening and prostate cancer mortality: results of the European randomised study of screening for prostate cancer (ERSPC) at 13 years of follow-up","volume":"384","author":"Schr\u00f6der","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.prp.2022.153897_bib4","article-title":"Prostate cancer screening with prostate-specific antigen (PSA) test: a clinical practice guideline","volume":"362","author":"Tikkinen","year":"2018","journal-title":"Bmj"},{"key":"10.1016\/j.prp.2022.153897_bib5","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0092-8674(04)00045-5","article-title":"MicroRNAs: genomics, biogenesis, mechanism, and function","volume":"116","author":"Bartel","year":"2004","journal-title":"cell"},{"key":"10.1016\/j.prp.2022.153897_bib6","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.cell.2009.01.002","article-title":"MicroRNAs: target recognition and regulatory functions","volume":"136","author":"Bartel","year":"2009","journal-title":"cell"},{"key":"10.1016\/j.prp.2022.153897_bib7","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/nrc1997","article-title":"MicroRNA signatures in human cancers","volume":"6","author":"Calin","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.prp.2022.153897_bib8","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/nature03702","article-title":"MicroRNA expression profiles classify human cancers","volume":"435","author":"Lu","year":"2005","journal-title":"nature"},{"key":"10.1016\/j.prp.2022.153897_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12935-015-0185-1","article-title":"MicroRNA (miRNA) in cancer","volume":"15","author":"Reddy","year":"2015","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.prp.2022.153897_bib10","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s12094-012-0877-0","article-title":"miRNAs as biomarkers in prostate cancer","volume":"14","author":"Casanova-Salas","year":"2012","journal-title":"Clin. Transl. Oncol."},{"key":"10.1016\/j.prp.2022.153897_bib11","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.eururo.2017.10.036","article-title":"Genomic markers in prostate cancer decision making","volume":"73","author":"Cucchiara","year":"2018","journal-title":"Eur. Urol."},{"key":"10.1016\/j.prp.2022.153897_bib12","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/146170","article-title":"MicroRNA as new tools for prostate cancer risk assessment and therapeutic intervention: results from clinical data set and patients\u2019 samples","volume":"2014","author":"Cannistraci","year":"2014","journal-title":"BioMed. Res. Int."},{"key":"10.1016\/j.prp.2022.153897_bib13","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1016\/j.juro.2011.11.082","article-title":"miR-21 as an independent biochemical recurrence predictor and potential therapeutic target for prostate cancer","volume":"187","author":"Li","year":"2012","journal-title":"J. Urol."},{"key":"10.1016\/j.prp.2022.153897_bib14","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1038\/bjc.2013.250","article-title":"The loss of the tumour-suppressor miR-145 results in the shorter disease-free survival of prostate cancer patients","volume":"108","author":"Avgeris","year":"2013","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.prp.2022.153897_bib15","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.biopha.2017.10.115","article-title":"Suppression of microRNA-454 impedes the proliferation and invasion of prostate cancer cells by promoting N-myc downstream-regulated gene 2 and inhibiting WNT\/\u03b2-catenin signaling","volume":"97","author":"Fu","year":"2018","journal-title":"Biomed. Pharmacother. Biomed. Pharmacother."},{"key":"10.1016\/j.prp.2022.153897_bib16","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18061281","article-title":"of MicroRNAs as diagnostic biomarkers for the identification of prostate cancer","volume":"18","author":"Daniel","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.prp.2022.153897_bib17","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1186\/s12935-020-01300-0","article-title":"miR-454 suppresses the proliferation and invasion of ovarian cancer by targeting E2F6","volume":"20","author":"An","year":"2020","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.prp.2022.153897_bib18","doi-asserted-by":"crossref","DOI":"10.3892\/or.2021.8078","article-title":"MicroRNA\u2011454\u20135p promotes breast cancer progression by inducing epithelial\u2011mesenchymal transition via targeting the FoxJ2\/E\u2011cadherin axis","volume":"46","author":"Wang","year":"2021","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.prp.2022.153897_bib19","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.canlet.2016.10.028","article-title":"Epigenetic disruption of miR-130a promotes prostate cancer by targeting SEC23B and DEPDC1","volume":"385","author":"Ramalho-Carvalho","year":"2017","journal-title":"Cancer Lett."},{"key":"10.1016\/j.prp.2022.153897_bib20","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1002\/pros.23031","article-title":"miR-130a activates apoptotic signaling through activation of caspase-8 in taxane-resistant prostate cancer cells","volume":"75","author":"Fujita","year":"2015","journal-title":"Prostate"},{"key":"10.1016\/j.prp.2022.153897_bib21","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/onc.2012.55","article-title":"MiR-130a, miR-203 and miR-205 jointly repress key oncogenic pathways and are downregulated in prostate carcinoma","volume":"32","author":"Boll","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.prp.2022.153897_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2018.07.014","article-title":"miR-301a expression: Diagnostic and prognostic marker for prostate cancer","volume":"36","author":"Kolluru","year":"2018","journal-title":"Urol. Oncol."},{"key":"10.1016\/j.prp.2022.153897_bib23","first-page":"3755","article-title":"MicroRNA\u2011301a\u20113p overexpression promotes cell invasion and proliferation by targeting runt\u2011related transcription factor 3 in prostate cancer","volume":"20","author":"Fan","year":"2019","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.prp.2022.153897_bib24","doi-asserted-by":"crossref","first-page":"7209","DOI":"10.1038\/s41388-020-01493-8","article-title":"MicroRNA determinants of neuroendocrine differentiation in metastatic castration-resistant prostate cancer","volume":"39","author":"Bhagirath","year":"2020","journal-title":"Oncogene"}],"container-title":["Pathology - Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033822001418?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033822001418?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T06:50:48Z","timestamp":1759733448000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0344033822001418"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":24,"alternative-id":["S0344033822001418"],"URL":"https:\/\/doi.org\/10.1016\/j.prp.2022.153897","relation":{},"ISSN":["0344-0338"],"issn-type":[{"value":"0344-0338","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Distinct expression signatures of miR-130a, miR-301a, miR-454 in formalin fixed paraffin embedded tissue samples of prostate cancer patients","name":"articletitle","label":"Article Title"},{"value":"Pathology - Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prp.2022.153897","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier GmbH. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"153897"}}